Program
tucidinostat
Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.
Drug pageTucidinostat: every studyAll 185 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciencesits history only | 92 open or running | phase 3since Jun 17, 2015 | Apr 12, 2013 | May 31, 2028phase 3 · NCT06497985 |
| HUYABIO International, LLC.its history only | 71 open or running | phase 3since Dec 7, 2020 | Oct 5, 2015 | none ahead |
| Great Novel Therapeutics Biotech & Medicalsits history only | 21 open or running | phase 2since Feb 7, 2023 | Feb 7, 2023 | Jun 2027phase 2 · NCT05833724 |
| Jiangsu HengRui Medicine | 11 open or running | phase 3since Nov 5, 2023 | Nov 5, 2023 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and Iqvia Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named tucidinostatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HBI-8000
- Nov 5, 2023First study: phase 3 study in RecurrenceFirst studyNCT06122389 · 130 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Jiangsu HengRui Medicine leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06122389Recurrence · China | 3 | Recruiting | May 2026 | 130 |
How it is read
Names in the registry
- “Chidamide”, 7 entries
- “Tucidinostat”, 4 entries
- “HBI-8000”, 4 entries
- “HBI-8000 in combination with nivolumab”, 2 entries
- “SHR2554 analog tablets; Chidamide”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Melanoma, 2 studies
- Breast Neoplasms, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.